-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Immunome, Raises Price Target to $35

Benzinga·08/12/2026 16:09:06
Listen to the news
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.